The CHIT1 inhibitor, synthetic drug OATD-01, targeting GH18 glycosidase active site, effectively mitigates inflammation driven by macrophages and indirectly influences fibroblast behavior, leading to decreased collagen deposition and a lowered fibrotic score in in vivo model of bleomycin-induced lung fibrosis (133). This evidence concerns the gene CHIT1 and pulmonary fibrosis.